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Purpose: A recent randomized phase III clinical trial in patients with glioblastoma 
demonstrated the efficacy of tumor treating fields (TTFields), in which alternating elec-
tric fields are applied via transducer arrays to a patient’s scalp. This treatment, when 
added to standard of care therapy, was shown to increase overall survival from 16 to 
20.9 months. These results have generated significant interest in incorporating the use 
of TTFields during postoperative concurrent chemoradiation. However, the dosimetric 
impact of high-density electrodes on the scalp, within the radiation field, is unknown.
Methods: The dosimetric impact of TTFields electrodes in the radiation field was 
quantified in two ways: (1) dose calculated in a treatment planning system and (2) phys-
ical measurements of surface and deep doses. In the dose calculation comparison, a 
volumetric-modulated-arc-therapy (VMAT) radiation plan was developed on a CT scan 
without electrodes and then recalculated with electrodes. For physical measurements, 
the surface dose underneath TTFields electrodes were measured using a parallel plate 
ionization chamber and compared to measurements without electrodes for various 
incident beam angles and for 12 VMAT arc deliveries. Deep dose measurements were 
conducted for five VMAT plans using Scandidos Delta4 diode array: measured doses on 
two orthogonal diode arrays were compared.
results: In the treatment planning system, the presence of the TTFields device caused 
mean reduction of PTV dose of 0.5–1%, and a mean increase in scalp dose of 0.5–1 Gy. 
Physical measurement showed increases of surface dose directly underneath by
30–110% for open fields with varying beam angles and by 70–160% for VMAT deliveries. 
Deep dose measurement by diode array showed dose decrease of 1–2% in most areas 
shadowed by the electrodes (max decrease 2.54%).
conclusion: The skin dose in patients being treating with cranial irradiation for glioblas-
toma may increase substantially (130–260%) with the addition of concurrent TTFields 
electrodes on the scalp. However, the impact of dose attenuation by the electrodes 
on deep dose during VMAT treatment is of much smaller, but measureable, magnitude 
(1–2%). Clinical trials exploring concurrent TTFields with cranial irradiation for glioblastoma 
may utilize scalp-sparing techniques to mitigate any potential increase in skin toxicity.
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inTrODUcTiOn
Glioblastoma remains the most common primary brain malig-
nancy, with more than 13,000 patients diagnosed in 2017 in the 
United States (1). The median overall survival for patients diag-
nosed with glioblastoma is dismal, ranging from 15 to 16 months 
in prospective randomized studies performed in the first decade 
of this century (2, 3). This median survival resulted from the 
introduction of temozolomide, an alkylating chemotherapy 
given concurrently and adjuvantly with radiation therapy (RT) 
after maximal safe neurosurgical resection; prior to the use of 
temozolomide, clinical trials routinely demonstrated a median 
survival of approximately 12 months. The poor prognosis of this 
disease has motivated clinical trials of radiation dose escalation, 
novel drug therapies, and other unconventional approaches. The 
most successful of these approaches has been the introduction 
of tumor treating fields (TTFields), in which alternating electric 
fields are applied via transducer arrays to a patient’s scalp. This 
technique has been demonstrated to have anti-mitotic activity 
in tumor cells and showed promise in patients with recurrent 
disease (4–7). The technique was applied in patients immediately 
after the conclusion of adjuvant chemoradiation in a randomized 
phase III study, which showed increased overall survival from 16 
to 20.9 months (8).
This remarkable improvement has generated significant inter-
est in the use of TTFields earlier in the treatment course—that 
is, during the course of postoperative concurrent chemoradia-
tion—in an attempt to evaluate the potential synergistic effect of 
multimodality therapy. However, the delivery of TTFields 
requires the placement of metallic transducer electrodes of high 
density onto the scalp of patients, directly into the radiation field. 
The dosimetric impact of an array of electrodes placed directly 
in the radiation field is not precisely known, and without this 
knowledge, estimation of the potential for toxicity with combined 
therapy is more difficult.
High-density objects on the surface of the patients receiving 
RT can have non-negligible and competing effects on the dose 
distribution in the patient’s body. On the one hand, the metal acts 
like additional buildup material, generating additional electrons 
via the photoelectric effect or Compton process. Clinically, this 
could translate into increased skin dose below the TTFields 
electrodes.
On the other hand, high-density materials can also act as an 
attenuator, reducing the dose to deeper tissues while simultane-
ously hardening the radiation beam via preferential attenuation 
of low energy photons. Clinically, this may impact the percent-
age depth dose curve and potentially decrease the target volume 
dose.
The present work is thus motivated by these physical principles, 
as well as the improvement in clinical outcomes with TTFields. 
We investigate both the buildup and attenuation/filtering effects 
of the TTFields electrode array on a scalp phantom, using both 
advanced dose calculation algorithms in the treatment planning 
environment and physical measurements of electrodes impact on 
surface and deep dose. We hypothesize that quantification of the 
dosimetric impact of the electrodes may facilitate the develop-
ment and execution of clinical trials evaluating combination 




The planning study was done on the Anderson RANDO phantom. 
A CT scan of the phantom was acquired, with and without the TTFields 
device. Target volumes and organs-at-risk contours from 10 patients 
previously treated for glioblastoma were used to generate clinical 
contours on the RANDO phantom. The target and normal tissues 
from these cases were transferred to the RANDO phantom and then 
modified by a radiation oncologist to be as realistic as possible.
These phantom patients were each planned using volumetric-
modulated-arc-therapy (VMAT) in Varian Eclipse® treatment 
planning system. Planning techniques were duplicated from the 
original clinical treatment plans for the number of arcs and the 
arc angle ranges. The metal electrodes from the TTFields treat-
ment devices were contoured on the CT scans and assigned a 
fixed density equal to the highest allowable value in each treat-
ment planning system, which is around the density of aluminum, 
to reduce the impact from metal artifacts on dose calculation and 
maintain consistent electrode positions between different phan-
tom plans. The dose calculation algorithm was set to AcurosXB 
v11 for its higher accuracy on calculating dose around high-Z 
materials (9).
All treatment plans were optimized on the scan without elec-
trodes, which is how patients would be scanned and simulated 
during an actual clinical treatment plan design process. The pre-
scription dose for all plans in this study was 60 in 2 Gy per fraction. 
Normal tissue objectives followed RTOG 0825 protocol: brainstem 
Dmax <  60  Gy, optical chiasm Dmax <  56  Gy, optical nerves 
Dmax < 55 Gy, lenses Dmax < 7 Gy, scalp Dmean < 20 Gy, scalp 
D20cc < 40 Gy, and scalp D10cc < 50 Gy. Plans were normalized 
so that the 100% prescription line covers 95% of the PTV volume. 
While keeping all plan parameters the same, the dose distribution 
was then recalculated on the phantom with the metal electrodes to 
assess the impact from the electrodes on key dosimetric parameters.
Paired comparison between treatment plans with and without 
electrodes were performed first for PTV coverage using percent-
age of PTV receiving at least Rx dose. The scalp dose was also 
compared to assess the dose buildup effect caused by the presence 
of metal object close to the skin. All comparisons were tested using 
Wilcoxon signed rank test to determine statistical significance.
Physical Measurements
To further evaluate the impact of skin and deep doses from the 
presence of the TTFields electrodes, physical measurements were 
also conducted.
Surface dose changes were measured using a parallel plate ioni-
zation chamber (10). The chamber was placed in the solid water 
phantom with 10 cm backscatter, and the surface of the chamber 
was matched with the surface of the phantom. To protect the cham-
ber, a 0.87 mm acrylic cap was placed on the front window of the 
parallel plate chamber, making the effective point of measurement 
at 1 mm depth in tissue equivalent media. The TTFields electrodes 
FigUre 1 | Measurements on deep dose impact from tumor treating fields 
(TTFields) electrodes conducted using the Delta4 volumetric-modulated-arc-
therapy QA platform. Blue and amber overlays showing the position and 
directions of orthogonal detector panels 1 and 2.
FigUre 2 | Dosimetric differences in PTV coverage and scalp dose as a result of including tumor treating field electrodes into dose calculation for 10 patients.
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were then placed on top of the acrylic cap to mimic placement on 
a patient’s scalp. The radius of active volume of the chamber was 
much less than the radius of the electrodes; therefore, the partial 
volume effect as a result of the electrode partially blocking the 
chamber was minimized. All measurements were first performed 
with 10 cm × 10 cm field size at 100 cm SSD. Charges were collected 
with and without TTFields electrodes for incident beam angles at 
−85, −75, 60, 30, 0, 30, 60, 75, and 85° relative to the axis perpen-
dicular to the surface of the chamber. In addition, surface doses 
with and without TTFields electrodes were also compared using 
actual VMAT plans delivered to a 20 cm × 20 cm × 20 cm solid 
water phantom. Surface doses for VMAT plans were measured with 
above-mentioned parallel plate chambers mounted with a special 
inset on the surface of the solid water phantom, with the chamber’s 
measurement window flush to the solid water phantom surface to 
mimic the actual scatter condition from the patient. Other in vivo 
dosimetry devices such as thermal luminescence dosimeter (TLD) 
or optically stimulated luminescence dosimeter (OSLD) were not 
chosen because of unavailability (TLD) and larger measurement 
uncertainty (~5% for OSLD).
In addition to surface dose, deep dose measurements were 
conducted using Delta4 device (Scandidos AB, Sweden) that are 
currently used clinically to verify all VMAT treatment in our clinic 
(11). As shown in Figure 1, this device has two planes of diode 
arrays that measures dose distribution within a cylindrical phan-
tom. To mimic clinical treatment with TTFields, the electrodes 
were placed directly onto the surface of the phantom where beams 
would enter. The measurements were compared with and without 
electrodes. Histograms and mean dose deviation were used to 
assess deep dose differences caused by the TTFields electrodes.
resUlTs
Plan Dosimetry evaluation
Figure 2 shows the difference in PTV coverage and scalp dose 
when comparing dose calculated with TTField electrodes in 
place against dose calculated without electrodes for 10 patients. 
In general, the calculated dose with the presence of electrodes 
decreased PTV coverage by 0.7 ± 0.4% in the treatment planning 
system. Dose to the scalp were slightly elevated when electrodes 
were taken into consideration during dose calculation. Mean 
scalp dose, as measured by the D1cc, D10cc, and D20cc were 
on average 0.5–1 Gy higher. Wilcoxon signed rank tests for all 
FigUre 4 | Surface dose increase factors plotted for different beam incident 
angles. Factors are normalized to the measurement taken at the same gantry 
angle without the electrodes.
FigUre 3 | Boxplot of scalp DVH parameters from treatment planning system comparing with and without tumor treating field (TTField) electrodes.
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paired dosimetric parameters and the differences between with 
and without TTFields electrodes indicated were all statistically 
significant, with p-values ranging from 0.002 to 0.004.
Figure 3 shows the distribution of scalp mean dose, D1cc, 
D10cc, and D20cc of plans calculated with and without taking 
electrodes into consideration. The impact of the electrodes on 
the distribution of the scalp DVH parameter is generally small. 
Doses calculated with electrodes were numerically higher 
than without, but the paired differences were small although 
statistically significant.
Physical Measurements—surface Dose
Figure 4 shows the surface dose increase due to the presence of 
the electrodes. The surface dose measured at different gantry angles 
were compared to measurement done at the same condition but 
without the electrodes, and the results were plotted against gantry 
angles. It is evident that the presence of the TTFields electrode 
introduced additional buildup effect that increased surface dose 
directly underneath. This buildup effect was the most pronounced 
at gantry 0, i.e., beam being perpendicular to the surface, caus-
ing surface dose to be 2.1 times measurement without TTFields 
electrodes. At large angles, i.e., beam being near tangent to the 
surface, the buildup factor is smaller, but still increases the surface 
dose underneath the electrode by approximately 30%.
Figure 5 shows the surface dose measurement comparison for 
five VMAT plans (12 VMAT arcs) with and without TTFields 
electrodes. In all cases, the presence of TTFields electrodes sig-
nificantly increased the surface dose measured by parallel plate 
chamber, by a mean ratio of 2.2 (range, 1.7–2.6), which was a 
larger effect than was measured in the open beam condition.
Physical Measurements—Deep Dose
Deep dose measurements for all five patients’ plans were shown in 
Figure 6. Regions around the center of the panels showed nega-
tive dose deviations, which corresponded to the locations that 
was shadowed by the TTFields electrodes. The pattern of the cold 
regions align well with the distribution of the individual electrodes 
FigUre 5 | Surface dose comparison for volumetric-modulated-arc-therapy 
deliveries for 12 arcs and 5 patients. On average, the ratio of surface dose 
between measurement with tumor treating field (TTFields) electrodes and the 
one without is 2.23.
FigUre 6 | Deep dose measurement conducted using Delta4™ quality assurance device. Black line separates the two measurement planes orthogonally arranged in the 
cylindrical phantom. Pixels are color coded according to the dose difference relative to the maximal dose in the plan. The scales are from −2% (deep blue) to +2% (deep red).
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on the TTFields device. Most regions affected by TTFields elec-
trodes showed a dose decrease of 1–2%. Because the radius of the 
phantom is similar to that of an adult’s head, the impact on deep 
dose in a clinical scenario where patient receives treatment with 
TTFields electrodes is likely to be in the similar range.
DiscUssiOn
Tumor treating fields has been gaining popularity in recent years 
as a treatment option for glioblastoma after completion of stand-
ard postoperative chemoradiation. In the clinical trials showing 
efficacy of TTFields, patients were prescribed to wear the device 
for greater than 18 h daily; this is not always feasible for patients. 
Utilizing the device in the setting of 6 weeks of daily radiation 
treatments may increase the logistical challenges to achieving 
high levels of compliance. From a clinical trial design standpoint, 
removing and replacing the electrodes on a daily basis to accom-
modate radiation may confound the outcome and increase skin 
irritation, since the electrodes are typically exchanged every 
2–3  days. As such, before embarking on a trial to evaluate the 
possible synergy of these treatment modalities, it is necessary 
to quantify the impact of these high-density electrodes on the 
dosimetry of radiation treatment. The present work provides 
radiation oncologists and physicists some quantitative guidelines 
on how to safely design treatment plans for the delivery of con-
current therapy.
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The results demonstrate that the presence of TTFields elec-
trodes has minimal impact on the deep dose to the planning target 
volume, which suggests that tumor dose would be unlikely to be 
compromised due to shadowing from the electrodes. Importantly, 
the physical deep dose changes measured in the phantom agreed 
with the dosimetric changes, which is reassuring.
This dosimetric and physical dose measurement agreement 
was not seen in the quantification of skin dose. While no sig-
nificant increase was observed in the treatment planning system 
using commonly evaluated DVH parameters such as scalp D1cc, 
physical measurements of surface dose increased when the 
electrodes were adhered to the surface by a factor of 1.3–2.6 in 
open field and VMAT deliveries. This result shows that additional 
caution must be taken into account for skin dose increase, which 
might not be evident in the DVH evaluation process. Scalp spar-
ing could be improved by using a 3 mm contraction ring from the 
skin surface with additional penalizing constraints during VMAT 
optimization. The detailed effectiveness and trade-offs for using 
this technique is currently under investigation.
The results also provided an important guideline for the design 
of radiation treatment plans for treating glioblastoma patients 
concurrently with the TTFields device. Due to the increased dose 
measured at the surface, some effort to spare the scalp may be 
clinically meaningful. Further, scalp dose constraints may need 
to be more conservative, in anticipation of the additional skin 
dose below the electrodes. While the toxicity rates will have to be 
measured prospectively, a conservative recommendation might 
be to limit skin dose during treatment planning between 30 and 
50% of published dose constraints.
There are several limitations of the current study. First, only 
one dose calculation algorithm was used in the planning study. 
For other does calculation algorithms and treatment planning 
systems, the difference between calculated dose with and 
without TTFields electrodes could be different, especially for 
the surface dose. Treatment planning systems have long had 
difficulty with accurate estimation of surface dose. However, as 
dose calculation algorithms improve, the accuracy of calculated 
skin/scalp dose is likely to be closer to measurements and may 
provide a more accurate skin dose estimation during treatment 
planning.
Second, although a parallel plate chamber was selected 
to ensure that dose is only measured at a very small depth 
(~1 mm), the measurement is limited by the large area of paral-
lel plate chamber in the direction parallel to the surface. This 
limitation can partially explain why VMAT deliveries had a 
higher surface dose increase than the largest increase found in 
open field delivery. The ionization chamber used in this study 
has an active collection volume with a diameter of ~1 cm, while 
VMAT deliveries consist of many small and rapidly changing 
fields and segments. For deliveries without TTFields electrodes 
on top of the chamber window, when the chamber volume is 
partially exposed to a VMAT segment, only charges generated 
in the partial volume are collected but averaged over the entire 
volume. This results in a partial volume effect, which leads to 
an under-response with VMAT deliveries. When TTFields 
electrodes were placed on top of the parallel plate chamber’s 
collection volume, they served to act as a buildup material. In the 
same small segment scenario described above, even though only 
a part of the chamber is exposed to primary photons, secondary 
electrons generated from the TTFields electrodes can still be 
scattered into the part of collection volume that is not exposed to 
the primary photon fluence. This effectively increases the paral-
lel plate chamber’s collection efficiency under the partial volume 
condition, which compensates for the partial volume effect and 
reduces the detector’s under-response. When the ratios between 
measurement with and without TTFields electrodes were calcu-
lated, the smaller denominator as a result of more pronounced 
partial volume effect could make the calculated ratio larger than 
actual value measured with a true point dose measurement.
When measuring deep dose, the TTFields electrodes were 
arranged to be in the same plane as the beam’s central axis of 
rotation. This maximized the likelihood of the electrodes being 
in the beam path. Therefore, the deep dose impacts detected in 
the above measurements likely represents a “worst case scenario.” 
In an actual clinical setting with patients wearing TTFields 
electrodes, the arrangement of TTFields electrodes will be 
non-coplanar and more random due to self-replacement by the 
patients, and the dosimetric impact is likely to be less than what 
was observed in the present work.
It is also important to note that the TTFields electrodes patches 
are disposable and regularly changed by patients. As the location 
of the electrodes will vary over the duration of RT, an effective 
averaging of the skin dose hot spots will be observed, which 
may reduce the maximal skin doses seen in any given region 
of the scalp. However, due to the uncertainty of this “hot spot 
averaging,” and in the absence of prospective data in patients, the 
authors recommend conservative scalp dose guidelines in clinical 
trials, with utilization of methods to reduce scalp dose as much 
as possible.
cOnclUsiOn
In this study, the impact from TTField electrodes on the dosim-
etry of VMAT treatment plans for patients with glioblastoma was 
quantitatively evaluated in two ways: (1) in the treatment planning 
system using advanced dose calculation algorithm and (2) using 
physical measurements on surface and deep doses. In general, 
the presence of electrodes decreases deep dose by ~1–2% 
confirmed by both treatment planning dose calculation and 
physical measurements. Skin dose underneath the electrodes 
at ~1 mm depth were measured to be 1.3 – 2.6 times the dose 
measured without the electrodes, representing an increase by 
30% to 160%; this effect was not evident from evaluation of 
scalp DVH parameters in the treatment planning system. The 
present work provides evidence that radiation doses to planning 
target volumes is not significantly changed due to the presence 
of TTFields electrodes, although the impact on skin dose was 
notable. As clinical trials to evaluate the potential synergy 
between TTFields and cranial irradiation are developed, care 
should be taken during treatment planning to reduce maximum 
scalp and skin doses well below published guidelines to reduce 
the risk of potential toxicity.
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